ITEM VIEW

Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa

dc.contributor.authorBock, Peteren_ZA
dc.contributor.authorFatti, Geoffreyen_ZA
dc.contributor.authorFord, Nathanen_ZA
dc.contributor.authorJennings, Karenen_ZA
dc.contributor.authorKruger, Jamesen_ZA
dc.contributor.authorGunst, Coletteen_ZA
dc.contributor.authorLouis, Francoiseen_ZA
dc.contributor.authorGrobbelaar, Nelisen_ZA
dc.contributor.authorShanaube, Kwameen_ZA
dc.contributor.authorFloyd, Sianen_ZA
dc.contributor.authorGrimwood, Ashrafen_ZA
dc.contributor.authorHayes, Richarden_ZA
dc.contributor.authorAyles, Helenen_ZA
dc.contributor.authorFidler, Sarahen_ZA
dc.contributor.authorBeyers, Nuldaen_ZA
dc.date.accessioned2020-05-21T19:33:33Z
dc.date.available2020-05-21T19:33:33Z
dc.date.issued2018-04-19
dc.identifier.citationBock, P., et al. 2018. Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa. PLoS ONE, 13(4):e0195127, doi:10.1371/journal.pone.0195127
dc.identifier.issn1932-6203 (online)
dc.identifier.otherdoi:10.1371/journal.pone.0195127
dc.identifier.urihttp://hdl.handle.net/10019.1/108585
dc.descriptionCITATION: Bock, P., et al. 2018. Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa. PLoS ONE, 13(4):e0195127, doi:10.1371/journal.pone.0195127.
dc.descriptionThe original publication is available at https://journals.plos.org/plosone/
dc.description.abstractIntroduction: WHO recommends antiretroviral treatment (ART) for all HIV-positive individuals. This study evaluated the association between baseline CD4 count and attrition in a cohort of HIV positive adults initiating ART at three department of health (DOH) clinics routinely providing ART at baseline CD4 counts >500cells/μL for the HPTN 071 (PopART) trial. Methods: All clients attending the DOH clinics were managed according to standard care guidelines with the exception that those starting ART outside of pertinent local guidelines signed research informed consent. DOH data on all HIV-positive adult clients recorded as having initiated ART between January 2014 and November 2015 at the three study clinics was analysed. Attrition, included clients lost to follow up or died, and was defined as ‘being three or more months late for an antiretroviral pharmacy pick-up appointment’. All clients were followed until attrition, transfer out or end May 2016. Results: A total of 2423 clients with a median baseline CD4 count of 328 cells/μL (IQR 195–468) were included of whom 631 (26.0%) experienced attrition and 140 (5.8%) were TFO. Attrition was highest during the first six months of ART (IR 38.3/100 PY; 95% CI 34.8–42.1). Higher attrition was found amongst those with baseline CD4 counts > 500 cells/μL compared to those with baseline CD4 counts of 0–500 cells/μL (aHR 1.26, 95%CI 1.05 to 1.52) This finding was confirmed on subset analyses when restricted to individuals non-pregnant at baseline and when restricted to individuals with follow up of > 12months. Conclusions:Attrition in this study was high, particularly during the first six months of treatment. Attrition was highest amongst clients starting ART at baseline CD4 counts > 500 cells/μL. Strategies to improve retention amongst ART clients, particularly those starting ART at baseline CD4 counts >500cells/μL, need strengthening. Improved monitoring of clients moving in and out of ART care and between clinics will assist in better understanding attrition and ART coverage in high burden countries.en_ZA
dc.description.urihttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0195127
dc.format.extent12 pagesen_ZA
dc.language.isoen_ZAen_ZA
dc.publisherPublic Library of Scienceen_ZA
dc.subjectAntiretroviral agenten_ZA
dc.subjectHIV-positive peopleen_ZA
dc.subjectCD4 antigenen_ZA
dc.titleAttrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africaen_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's version
dc.rights.holderAuthors retain copyrighten_ZA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW